Previous studies have confirmed that the novel FAP-targeted tracers labeled with 68Ga demonstrated a higher sensitivity and tumor-to-nontumor contrast ratios than those attained with 2-[18F]F-FDG PET/CT in several different types of malignant tumors11,16,17. The gene discussed is FAP; the disease is neoplasm.